Cullinan Therapeutics (CGEM) Change in Account Payables (2020 - 2026)

Cullinan Therapeutics' Change in Account Payables history runs 7 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• In Q1 2026, Change in Account Payables fell 3.08% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at -$892000.0 (down 191.5% YoY), while the FY2025 annual figure was -$839000.0, down 3.33% from the prior year.
• Change in Account Payables for Q1 2026 stood at $1.7 million, up from -$879000.0 in the prior quarter.
• The five-year high for Change in Account Payables was $3.1 million in Q1 2022, with the low at -$3.2 million in Q2 2022.
• The 5-year median for Change in Account Payables is -$434000.0 (2024), against an average of -$38823.5.
• Peak annual rise in Change in Account Payables reached 292.7% in 2024, while the deepest fall reached 566.81% in 2024.
• Cullinan Therapeutics' Change in Account Payables stood at $1.1 million in 2022, then surged by 34.67% to $1.5 million in 2023, then sank by 128.15% to -$434000.0 in 2024, then slumped by 102.53% to -$879000.0 in 2025, then surged by 289.65% to $1.7 million in 2026.
• Business Quant data shows CGEM's Change in Account Payables at $1.7 million in Q1 2026, -$879000.0 in Q4 2025, and -$739000.0 in Q3 2025.